{"groups":[{"description":"Participants received 300 mg azacitidine tablets once a day (QD) for the first 14 days of each 28-day treatment cycle until discontinuation, which includes the following reasons: disease relapse, withdrawal of consent, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, death, lost to follow-up, or protocol violation or until the end of the study.","id":"FG000","title":"Oral Azacitidine Plus Best Supportive Care"},{"description":"Participants received identically matching placebo tablets QD for the first 14 days of each 28-day treatment cycle until no longer receiving benefit, withdrawal of consent, disease relapse, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, lost to follow-up, or protocol violation or until the end of the study.","id":"FG001","title":"Placebo Plus Best Supportive Care"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"151"},{"groupId":"FG001","numSubjects":"181"}],"type":"Disease Relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"27"}],"type":"Other Reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"11"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"13"}],"type":"Withdrew Consent"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"238"},{"groupId":"FG001","numSubjects":"234"}],"comment":"Treatment Phase","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"236"},{"groupId":"FG001","numSubjects":"233"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"238"},{"groupId":"FG001","numSubjects":"234"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"472 Participants Randomized, 469 participants treated"}